Owlstone Medical joins EU-funded EPHOR consortium to advance occupational health science
Owlstone Medical, the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announced it has joined the EU-funded Exposome Project for Health and Occupational Research (EPHOR). The consortium aims to further elucidate the complex relationships between environment and disease by developing the concept of the ‘working-life exposome’, which takes…
Breath Biopsy Conference doubles in size
The 2019 Breath Biopsy Conference – Owlstone Medical's community meeting for breath researchers – took place in Cambridge on 13th and 14th November.
Owlstone Medical enters collaboration to advance early disease detection using non-invasive breath biopsy
Owlstone Medical, the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announced it has partnered with Thermo Fisher Scientific, the world leader in serving science. The collaboration seeks to advance the application of non-invasive breath sampling to address the challenges of the early detection of disease and the precision medicine…
Owlstone Medical to contribute breath biopsy to 3TR, the largest-ever IMI2 immunology project
Owlstone Medical, the global leader in Breath Biopsy® for applications in early disease detection and precision medicine has joined 3TR, a large-scale public-private research initiative that aims to provide new insights into the mechanisms of response and non-response to treatment within and across seven different immune-mediated diseases.
Cleveland Clinic and Owlstone Medical partner to establish a new Center for Early Disease Detection
Cleveland Clinic is partnering with Owlstone Medical to establish a new Center for Early Disease Detection. The Center will investigate the use of measuring and quantifying volatile organic compounds (VOCs) in exhaled breath, in combination with other non-invasive biomarkers from other bodily fluids such as saliva and blood, for the early detection of multiple diseases from chronic conditions to…
Owlstone Medical announces advancements in breath biopsy platform including next generation ReCIVA Breath Sampler and CASPER Portable Air Supply
Owlstone Medical, the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announced the introduction of a new ReCIVA® Breath Sampler and CASPERTM Portable Air Supply, designed to support internal biomarker discovery programmes and those of academic and biopharma clients, and to measure levels of known volatile organic compounds (VOCs) on…
Breath Biopsy Conference 2019 - register your interest now
The Breath Biopsy Conference 2019 - Owlstone Medical's community meeting for breath researchers- will take place on 13th and 14th November in Cambridge.
Owlstone Medical announces a novel approach to breath-based testing for investigation of the onset, progression, and treatment of disease
Owlstone Medical, the global leader in Breath Biopsy® for applications in early disease detection and precision medicine, today announces the development of an innovative alternative approach to breath-based testing through the utilization of Exogenous Volatile Organic Compound (EVOC®) Probes. The novel probes will enable Breath Biopsy to be deployed for a wider range of applications.
Owlstone Medical announces new partnership to identify breath biomarkers for early detection of malignant mesothelioma
Owlstone Medical, a global diagnostics company developing a breathalyzer for applications in early disease detection and precision medicine, forms a new partnership with a building trades union in the US and Canada, to identify and verify breath-based biomarkers for the early detection of malignant mesothelioma.
Owlstone Medical enters into a strategic collaboration with Actelion
Owlstone Medical and Actelion collaborate to develop a breath-based test to help facilitate early detection of pulmonary hypertension.
University of Manchester and Owlstone Medical partner for asthma diagnostic development
The University of Manchester and Owlstone Medical, a global diagnostics company developing a breathalyzer for applications in early disease detection and precision medicine, today announce the award of an Asthma UK/Innovate UK grant for the improvement of asthma diagnosis.
Owlstone Medical and Shanghai Hospital to pioneer breath biopsy lung cancer trial in China
Owlstone Medical Ltd., a global diagnostics company developing a breathalyzer for applications in early disease detection and precision medicine, and Shanghai Renji Hospital, today announced a collaboration to conduct a clinical trial into the early detection of lung cancer with support from the Li Ka Shing Foundation.
Clinical trial launches to develop breath test for multiple cancers
Owlstone Medical, a global diagnostics company developing a breathalyzer for applications in early disease detection and precision medicine, and Cancer Research UK, today announce the clinical launch of the PAN Cancer trial for Early Detection of Cancer in Breath(1), with the first patients now being recruited for the 1,500 patient study.
Breath Biopsy Conference attracts over 100 researchers
Last week the inaugural Breath Biopsy Conference took place in the Cambridge Science Park, UK.
Owlstone Medical appoints Dr Richard A Yost to Scientific Advisory Board
Owlstone Medical, a global diagnostics company developing a breathalyzer for applications in early disease detection and precision medicine, today announces the appointment of Dr Richard A Yost to its Scientific Advisory Board.
Owlstone Medical completes $50m (c.£38m) financing round
Owlstone Medical Ltd, a global diagnostics company developing a breathalyzer for applications in early disease detection and precision medicine, announced that it has completed its financing round to drive the global commercialization of its Breath Biopsy platform.
Owlstone Medical appoints Dr Andy Richards CBE to Board of Directors
Owlstone Medical Ltd, a global diagnostics company developing a breathalyzer for early disease detection and precision medicine, announced today the addition of Dr Andy Richards CBE to its Board as a Non-Executive Director.
Owlstone Medical appoints five leading experts to Scientific Advisory Board
Owlstone Medical (or the “Company”), a diagnostics company developing a breathalyzer for disease, has announced the expansion of its Scientific Advisory Board (SAB) with the appointment of five leading experts in a range of high value disciplines as the Company expands and drives towards its goal of saving 100,000 lives and saving healthcare providers $1.5 billion.
Owlstone's Breath Biopsy platform scoops UK's most prestigious innovation award
The Royal Academy of Engineering reveals Owlstone Medical, creators of the ReCIVA Breath Sampler, as the winners of the 2018 MacRobert Award.
Owlstone Medical in the running for top UK innovation prize
Cambridge-based Owlstone Medical is a finalist in the running for the UK’s most prestigious innovation award, the Royal Academy of Engineering MacRobert Award, continuing a tradition of success for local technology companies.
Owlstone Medical is shortlisted for European Mediscience Awards 2018
Owlstone Medical is excited to be shortlisted for The Emerging Star Award of the European Mediscience Awards 2018.
Owlstone Medical provides breath biopsy services to AstraZeneca
Owlstone Medical, a diagnostics company developing a breathalyzer for disease, announced it has signed a service agreement with AstraZeneca plc, a global biopharmaceutical company. The collaboration will explore how breath can be used to identify novel biomarkers to help differentiate between disease phenotypes relevant for asthma and COPD.
Owlstone Medical launches Breath Biopsy Kits
Owlstone Medical, a diagnostics company developing a breathalyzer for disease, today announced the launch of its Breath Biopsy® Kits, based on the company’s proprietary Breath Biopsy platform. The new product range allows academic, clinical and pharmaceutical researchers to quickly discover and validate breath-based biomarkers in early detection and precision medicine research activities.
Owlstone Medical raises £11 million with Horizons Ventures and Aviva
Owlstone Medical Ltd, a diagnostics company developing a breathalyzer for disease, announced today that it has raised $15 million (£11 million) to drive the global commercialization of its Breath Biopsy® platform. The funds will enable the company to bring its lung cancer Breath Biopsy test to market, deepen the early detection pipeline with ongoing trials across multiple cancers, and further…
Owlstone Medical’s breath biopsy wins global IPF Catalyst Challenge
Owlstone Medical Ltd, a diagnostics company developing a breathalyzer for disease, is one of the three winners of the global Idiopathic Pulmonary Fibrosis (IPF) Catalyst Challenge, sharing the $1million (£720,000 GBP) award, each receiving $333,333 (£240,000 GBP).